docetaxel anhydrous has been researched along with Disease Exacerbation in 581 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (1.89) | 18.2507 |
| 2000's | 210 (36.14) | 29.6817 |
| 2010's | 317 (54.56) | 24.3611 |
| 2020's | 43 (7.40) | 2.80 |
| Authors | Studies |
|---|---|
| Fruehauf, JP; Lilly, M; Uchio, E; Zhuang, E; Zi, X | 1 |
| Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Arya, S; Chaturvedi, P; Chaukar, D; D'Cruz, A; Deshmukh, A; Ghosh-Laskar, S; Nair, D; Nair, S; Noronha, V; Pai, PS; Pantvaidya, G; Patil, A; Patil, VM; Prabash, K; Rane, P; Sharma, S; Thiagarajan, S; Vaish, R | 1 |
| Ando, M; Asami, K; Atagi, S; Kawahara, M; Minato, K; Mori, M; Nishimura, T; Ogushi, F; Tamura, A; Yamamoto, A; Yokoi, T; Yoshioka, H | 1 |
| Ahmed, ME; Alamiri, J; Andrews, JR; Bold, MS; Britton, CJ; Dundar, A; Higa, JL; Karnes, RJ; Kendi, AT; Kwon, E; Lowe, VJ; Pagliaro, LC | 1 |
| Chen, J; Liu, S; Ma, G; Song, W; Wang, H; Yu, G | 1 |
| Dong, X; Gai, F; Gong, H; Guo, J; Han, X; Hua, Y; Huang, W; Huang, Z; Liu, Z; Meng, X; Sun, Y; Tang, X; Wang, L; Wang, Z; Yuan, S; Zhang, P; Zhang, X; Zhang, Y; Zhu, C; Zhu, D; Zhu, H | 1 |
| Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Nakano, Y; Okamura, Y; Terakawa, T | 1 |
| Basch, EM; de Bono, JS; Fizazi, K; Pond, GR; Scher, HI; Smith, MR; Sonpavde, GP | 1 |
| Agrawal, S; Antonia, SJ; Borghaei, H; Brahmer, J; Burgio, MA; Butts, C; Chow, LQM; Crinò, L; De Castro Carpeño, J; Drilon, A; Garassino, M; Gettinger, S; Horn, L; Li, A; Otterson, GA; Penrod, JR; Planchard, D; Pluzanski, A; Ramalingam, SS; Wojcik-Tomaszewska, J | 1 |
| Chi, C; Dong, B; Karnes, RJ; Pan, J; Qian, H; Sha, J; Shao, X; Wang, Y; Xu, F; Xue, W; Zhu, Y | 1 |
| Ali, A; Amos, CL; Attard, G; Beesley, S; Birtle, A; Brawley, CD; Brown, J; Calvert, J; Capaldi, L; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gale, J; Gibbs, S; Gilbert, D; Gillessen, S; Hoyle, A; Ingleby, FC; James, ND; Jones, RJ; Langley, RE; Lydon, A; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Nikapota, A; O'Sullivan, JM; Omlin, A; Parikh, O; Parker, CC; Parmar, MKB; Protheroe, A; Ritchie, AWS; Rudman, S; Rush, H; Russell, JM; Simms, M; Srihari, NN; Sydes, MR; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A | 1 |
| Barbano, R; Copetti, M; Esteller, M; Fazio, VM; Fontana, A; Graziano, P; Maiello, E; Mazza, T; Morritti, M; Murgo, R; Parrella, P; Pasculli, B; Rendina, M; Valori, VM | 1 |
| Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A | 1 |
| Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S | 1 |
| Alexandris, E; Brustugun, OT; Cuyun Carter, G; Gans, S; Garon, EB; Gautschi, O; Iglesias Docampo, L; Kalofonos, H; Kim, JH; Lee, P; Orlov, SV; Oton, AB; Pérol, M; Reck, M; Scagliotti, GV; Socinski, MA; Stefaniak, VJ; Thomas, M; Wolff, K; Zimmermann, AH | 1 |
| Asao, T; Hara, K; Hisada, T; Imai, H; Jingu, A; Kaira, K; Kasahara, N; Kitahara, S; Koga, Y; Kuwako, T; Maeno, T; Masuda, T; Mori, K; Naruse, I; Sakurai, R; Sunaga, N; Tsukagoshi, Y; Tsurumaki, H; Yatomi, M | 1 |
| Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M | 1 |
| Gao, WQ; Li, L; Liu, L; Liu, Y; Tong, Y; Wang, F | 1 |
| Almassi, N; Carducci, MA; Chen, YH; DiPaola, RS; Dreicer, R; Garcia, JA; Hearn, JWD; Hobbs, B; Jarrard, DF; Li, H; Reddy, CA; Reichard, CA; Sharifi, N; Sweeney, CJ | 1 |
| Dercle, L; Du, S; Fojo, AT; Fronheiser, M; Guo, P; Hayes, W; Leung, DK; Lu, L; Roy, A; Schwartz, LH; Wilkerson, J; Zhao, B | 1 |
| Bukhari, N; Haider, G; Hussain, S; Mehar, K; Memon, P; Nouman, M; Nouman, R; Pavan, B; Rahool, R; Sami, A; Shaikh, MR; Yousuf, A; Zahoor, S | 1 |
| Cai, Z; Chen, C; Jiang, F; Li, J; Lin, Z; Liu, Z; Wan, Y; Xi, M; Zheng, Y; Zhong, W; Zhou, X; Zhu, J; Zhuo, Y | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Pfail, J | 1 |
| Arriola, E; Cui, ZL; Garon, EB; Levy, B; Mekhail, T; Molife, C; Pérol, M; Winfree, KB | 1 |
| Eterović, D; Omrčen, T; Vrdoljak, E | 1 |
| Beltran, H; Clinton, SK; Coleman, J; Eastham, JA; Evans, CP; George, S; Gleave, M; Hahn, OM; Halabi, S; Heller, G; Hillman, DW; Mohler, JL; Monk, JP; Morris, MJ; Parsons, JK; Sanda, MG; Small, EJ; Szmulewitz, RZ; Taplin, ME; Watt, CR | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Bryce, AH; Carducci, MA; Chen, YH; DiPaola, RS; Dreicer, R; Eisenberger, MA; Garcia, JA; Harshman, L; Hussain, M; Jarrard, DM; Liu, G; Plimack, ER; Sweeney, CJ; Vogelzang, NJ | 1 |
| Gao, J; Liu, XL; Lu, HX; Yang, MD; Yang, WH | 1 |
| Aghai, A; Chen, M; de Morrée, ES; de Ridder, CMA; de Wit, R; Erkens-Schulze, S; Gibson, A; Lolkema, MP; Mathijssen, RHJ; Moll, JM; Mout, L; Sparreboom, A; Stuurman, D; van Weerden, WM | 1 |
| Bajaj, A; Dasgupta, U; Kar, A; Komalla, V; Kumar, S; Mukhopadhyay, A; Pal, S; Sengupta, S; Sharma, H; Sharma, RD; Sharma, Y; Shyam, R; Sreekanth, V; Yadav, P | 1 |
| Pienta, KJ; Reyes, DK; Rowe, SP; Sheikhbahaei, S | 1 |
| Brown, J; Cunningham, J; Gatenby, R; Peeters, R; Staňková, K; Thuijsman, F; Viossat, Y | 1 |
| Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S | 1 |
| Antonia, S; Arrieta, O; Barlesi, F; Borghaei, H; Brahmer, J; Burgio, MA; Butts, C; Chiari, R; Chow, LQM; Coudert, B; Crino, L; Czyzewicz, G; de Castro Carpeno, J; Domine, M; Eberhardt, WEE; Felip, E; Frontera, OA; Garassino, MC; García, MA; Gerber, DE; Gettinger, S; Li, A; Marimuthu, S; Pluzanski, A; Ready, N; Spigel, DR; Vokes, EE; Waterhouse, D; Wohlleber, M; Wójcik-Tomaszewska, J | 1 |
| Kurokawa, T; Maeda, H; Takeda, K; Urushihara, H | 1 |
| Agarwal, N; Coletta, AM; Sayegh, N | 1 |
| Abrial, C; Atger, M; Chollet, P; Durando, X; Eymard, JC; Ginzac Couvé, A; Kwiatkowski, F; Mahammedi, H; Monange, B; Passildas-Jahanmohan, J; Pouget, M; Richard, D; Savareux, L; Thivat, E; Van Praagh, I | 1 |
| Ballinger, M; Cardona, A; Gadgeel, S; Gandara, D; Mazieres, J; Mendus, D; Moro-Sibilot, D; Morris, S; Peters, S; Reck, M; Rittmeyer, A | 1 |
| Bai, H; Han, Y; Niu, Y; Zhang, M | 1 |
| Abdeddaim, C; Fortpied, C; Remenár, É; Stewart, JS; Szturz, P; van Herpen, CML; Vermorken, JB; Vinches, M | 1 |
| Hisada, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Miura, Y; Mori, K; Saito, R; Sakurai, R; Tomizawa, Y | 1 |
| Barlesi, F; Blackhall, F; Bowen, K; Carlile, DJ; Cobo, M; Crinò, L; Garrido, P; Ghiorghiu, D; Jänne, PA; Kilgour, E; Kohlmann, A; Lawrence, D; Mariani, G; Mazieres, J; Orlov, S; Poltoratskiy, A; Smith, P; van den Heuvel, MM; Vansteenkiste, J; Wolf, J | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Hinz, S | 1 |
| Alegre Del Rey, EJ; Asensi Díez, R; García de Paredes Esteban, JC | 1 |
| Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
| Antonarakis, ES; Harshman, LC; Kantoff, PW; Lee, GM; Maughan, BL; McKay, R; Mucci, LA; Nakabayashi, M; Pomerantz, M; Sweeney, CJ; Taplin, ME; Tripathi, A; Wang, X; Werner, L | 1 |
| Boher, JM; Culine, S; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Marino, P; Oudard, S; Sfumato, P | 1 |
| Alhasso, A; Carruthers, R; Cascales, A; Dodds, D; Glen, H; Jones, RJ; Lamb, C; Laskey, J; MacLeod, N; Marashi, H; McKay, S; Neilson, S; Rulach, RJ; Russell, JM; Sadoyze, A; Sidek, N; Venugopal, B; Wallace, J; White, L | 1 |
| Chan, ALF; Leung, HWC; Leung, JH; Muo, CH | 1 |
| Eisterer, W; Fridrik, MA; Greil, R; Gruenberger, B; Hejna, M; Huemer, F; Keil, F; Thaler, J; Trommet, V; Ulmer, H; Weiss, L; Wöll, E | 1 |
| Asano, Y; Goto, W; Hatano, T; Hirakawa, K; Kashiwagi, S; Motomura, H; Ohira, M; Ohsawa, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S | 1 |
| Ohlmann, CH | 1 |
| Castelnau, O; Cohen, C; Mouroux, J; Otto, J; Pop, D; Poudenx, M; Venissac, N | 1 |
| Chikazawa, I; Inoue, S; Miyazawa, K; Morita, N; Motoo, Y; Nakai, D; Nakazawa, Y; Tanaka, T | 1 |
| Enokida, H; Inoue, S; Ishibashi, K; Izumi, K; Kamiyama, M; Kawai, N; Mizokami, A; Namiki, M; Shima, T; Takahara, S; Tanaka, N; Yoshio, Y | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Alexandris, E; Bidoli, P; Borghaei, H; Cappuzzo, F; Carter, GC; Chan-Diehl, F; Dakhil, S; Johnson, M; Jotte, R; Lee, P; Moro-Sibilot, D; Paz-Ares, L; Pennell, NA; Pérol, M; Reck, M; Sashegyi, A; Shepherd, FA; Thomas, M; Tsao, A; Zimmermann, A | 1 |
| Cai, C; Duan, X; Kong, Z; Lai, Y; Li, S; Wu, W; Xu, S; Zeng, T; Zhao, Z | 1 |
| Ahlgren, GM; Angelsen, A; Borre, M; Flodgren, P; Iversen, JR; Jonsson, E; Kellokumpu-Lehtinen, P; Sengelov, L; Sverrisdottir, A; Tammela, TLJ | 1 |
| Boerner, J; Dobson, K; Fontana, J; Heath, E; Heilbrun, L; Li, J; Smith, D; Stark, K; Thakur, MK; Vaishampayan, U | 1 |
| Angelergues, A; Balea, BC; Bellmunt, J; Birtle, AJ; Borrega, P; Carbonero, IG; Castellano, DE; Delanoy, N; Efstathiou, E; Esteban, E; Flechon, A; Gonzalez, I; Guillot, A; Gyftaki, R; Lainez, N; Le Moulec, S; Munarriz, J; Oudard, S; Ozguroglu, M; Rubio, G; Wysocki, PJ | 1 |
| Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Ohsawa, M; Takada, K; Takashima, T | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Kaneko, Y; Takayama, K; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, K | 1 |
| Ahn, MJ; Chang, WJ; Choi, MK; Hong, JY; Jung, HA; Kim, HS; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A | 1 |
| Harris, AR; Munson, JM; Perez, MJ | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| Goto, K; Horinouchi, H; Kato, T; Kenmotsu, H; Morsli, N; Nakagawa, K; Saito, I; Sarashina, A; Takeda, K; Takeda, M; Tanaka, T; Yamamoto, N | 1 |
| Abdel-Rahman, O; Cheung, WY | 1 |
| Cristofanilli, M; DiNatale, A; Fatatis, A; Kaur, R; Meucci, O; Qian, C; Shen, F; Worrede-Mahdi, A; Zhang, Q | 1 |
| Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F | 1 |
| Basso, U; Caffo, O; Campadelli, E; Conteduca, V; De Giorgi, U; Facchini, G; Fratino, L; Gasparro, D; Kinspergher, S; Maines, F; Massari, F; Messina, C; Mosillo, C; Procopio, G; Rossetti, S; Sabbatini, R; Sava, T; Scagliarini, S; Sirotova, S; Veccia, A; Verzoni, E | 1 |
| Hofer, MD | 1 |
| Abogunrin, S; De Porre, P; Diels, J; Feyerabend, S; Fizazi, K; Ito, T; Koufopoulou, M; Li, T; Roiz, J; Saad, F; Van Sanden, S | 1 |
| Bao, Y; Chai, J; Chen, X; Gao, H; Liu, H; Shi, S; Yu, K; Zou, L | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Ahn, MJ; Burtness, B; Cheng, J; Cohen, EEW; Dinis, J; Harrington, KJ; Le Tourneau, C; Licitra, L; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Zhang, P | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Barrueco, J; Grohé, C; Hilberg, F; Huber, RM; Kaiser, R; Kerr, KM; Manegold, C; Park, K; Pavlakis, N; Paz-Ares, L; Popat, S; Reck, M; Thatcher, N | 1 |
| Hasegawa, Y; Kawahara, T; Kumano, Y; Matsubara, N; Miyoshi, Y; Uemura, H; Yasui, M | 1 |
| Hashimoto, K; Kagamu, H; Kaira, K; Kobayashi, K; Miura, Y; Mouri, A; Murayama, Y; Nishihara, F; Shiono, A; Uchida, T; Yamaguchi, O | 1 |
| He, W; Li, L; Li, Z; Liu, T; Ren, Y; Wang, J; Yan, M; Zhang, Y | 1 |
| Guo, J; He, D; Huang, Y; Jin, J; Li, H; Ma, L; Shan, Y; Sun, Z; Wei, Q; Xiao, J; Ye, D; Zhang, Z | 1 |
| Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X | 1 |
| Chen, E; Evans, A; Hansen, AR; Joshua, AM; Knox, J; Prawira, A; Sridhar, SS; Tan, S; Tannock, IF; Templeton, A; Vera-Badillo, F; Wang, L; Wouters, BG | 1 |
| Cocks, K; Contente, M; DeRosa, M; Shaw, JW; Simpson, S; Taylor, FC | 1 |
| Cai, QL; Li, G; Niu, YJ; Wang, Z; Xu, J; Yang, X; Zhang, HT; Zhu, SM | 1 |
| Fang, XD; Hu, X; Jiang, Q; Ma, DY; Tan, BX; Zhang, NL | 1 |
| de Castro, J; Felip, E; García-Campelo, R; Garrido, P; Isla, D; Lianes, P; Paz-Ares, L; Trigo, JM | 1 |
| Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I | 1 |
| Choi, CM; Choi, MG; Ji, W; Kim, HR; Lee, GD; Lee, JC; Oh, DK; Park, S | 1 |
| Hamada, K; Imataka, H; Nemoto, H; Sato, A; Takeda, N | 1 |
| Adjei, A; Brenner, DE; Cease, KB; Daignault-Newton, S; Dy, GK; Elingrod, VL; Johnson, CS; Kalemkerian, GP; Muindi, JR; Ramnath, N; Stella, PJ; Troeschel, S; Trump, DL | 1 |
| Alici, S; Alkis, N; Altunbas, M; Arpaci, E; Benekli, M; Bilici, A; Buyukberber, S; Dane, F; Demirci, U; Gumus, M; Karaca, H; Ozkan, M; Turk, HM | 1 |
| Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J | 1 |
| Fizazi, K; Fizazi, KS; Gleave, M; Higano, CS; McIntosh, S; Miller, K; Morris, T; Moul, JW; Nathan, FE; Nelson, JB; Pemberton, K | 1 |
| Chen, JP; Chen, XL; Chen, XZ; Chen, ZX; Hu, JK; Li, H; Li, K; Liao, YB; Wang, L; Yang, C; Yang, K; Zhang, B; Zhou, ZG | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Daugaard, G; Pappot, H; Pawlak, WZ; Petersen, PM; Rørth, M; Urup, T | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Autio, KA; Carrasquillo, JA; Heller, G; Hong, C; Larson, SM; Morris, MJ; Pandit-Taskar, N; Rathkopf, DE; Scher, HI; Slovin, SF; Stephenson, RD | 1 |
| Jeong, S; Ki, SH; Kim, HG; Kwon, KS; Lee, DH; Lee, JI; Park, IS; Shin, YW | 1 |
| Boegemann, M; Cronauer, MV; Hajili, T; Herrmann, E; Jentzmik, F; Krabbe, LM; Ohlmann, CH; Schnoeller, TJ; Schrader, AJ; Schrader, M; Stoeckle, M | 1 |
| Arranz, JÁ; Bellmunt, J; Gallardo, E; León, LÁ; Maroto, JP | 1 |
| Ahallal, Y; Barret, E; Bennamoun, M; Cathelineau, X; Cerruti, J; Durand, M; Galiano, M; Gaya, JM; Macek, P; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R | 1 |
| Aggarwal, R; Carducci, M; George, D; Halabi, S; Kantoff, P; Kelly, WK; Mahoney, JF; Millard, F; Monk, JP; Morris, MJ; Small, EJ; Stadler, WM | 1 |
| Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S | 1 |
| de Wit, R; Eisenberger, MA; Epstein, JI; Huang, P; Kattan, MW; Kibel, AS; Schweizer, MT; Sternberg, CN | 1 |
| Gallego, IG; Garcia-Carbonero, R; Giménez, EV; Giuliani, R; Gravanis, I; Hemmings, RJ; Jiménez, JC; Lopez, AS; O'Connor, D; Pignatti, F; Salmonson, T | 1 |
| Berruti, A; Caffo, O; Chierichetti, F; Galligioni, E; Maines, F; Palermo, A; Veccia, A | 1 |
| Dillon, PM; Greer, KE; Marchetti, MA; Noland, MM | 1 |
| Button, MR; Evans, J; Kumar, S; Lester, JF; Palaniappan, N; Smith, C; Staffurth, J; Tanguay, JS; Thomas, BM | 1 |
| Chen, XS; Du, J; Tian, J; Yang, Q; Yao, X | 1 |
| La Flamme, AC; Miller, JH; Northcote, PT; O'Sullivan, D | 1 |
| Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C | 1 |
| Hadjiandreou, MM; Mitsis, GD | 1 |
| Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R | 1 |
| Araujo, JC; Armstrong, AJ; Begbie, S; Bellmunt, J; Cheng, S; de Bono, JS; Durham, S; Efstathiou, E; Gallardo, E; Goebell, PJ; Heidenreich, A; Hong, JH; Logothetis, CJ; Matveev, VB; McCaffrey, J; Morris, MJ; Oudard, S; Paliwal, P; Richardet, E; Saad, F; Serrano, SV; Sizer, B; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV | 1 |
| Caton, J; Chittoor, S; Cohn, A; Garbo, L; Katz, T; Kim, ES; Neubauer, M; Reynolds, C; Robert, F; Saxman, S; Schwartzberg, L; Simms, L | 1 |
| Hata, M; Inoue, T; Kioi, M; Koike, I; Koizumi, T; Mitsudo, K; Mukai, Y; Oguri, S; Omura, M; Tohnai, I | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Ding, CM; He, ZY; Li, K; Li, WL; Liu, W; Mao, WD; Sun, T; Wang, HM; Wang, J; Yao, Q; Zhang, MJ; Zhang, Y; Zhou, XL | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Leibowitz-Amit, R; Peer, A; Sella, A; Sinibaldi, V | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gann, CN; Gaschler-Markefski, B; Gottfried, M; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; von Pawel, J | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ | 1 |
| Azuma, K; Hoshino, T; Mizoguchi, Y; Naito, Y; Okayama, Y; Takeoka, H; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC | 1 |
| Petrylak, DP | 1 |
| Anai, S; Fujii, T; Fujimoto, K; Konishi, N; Shimada, K; Tanaka, N | 1 |
| Autenrieth, M; Eiber, M; Gschwend, JE; Heck, MM; Herkommer, K; Horn, T; Krause, BJ; Kübler, HR; Maurer, T; Retz, M; Thalgott, M; Treiber, U | 1 |
| Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T | 1 |
| Li, J; Liu, Y; Ma, J; Montgomery, B; Wang, LZ; Yang, CZ; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, DW | 1 |
| Mizokami, A; Namiki, M | 1 |
| Aggarwal, R; Formaker, C; Griffin, TW; Harris, A; Molina, A; Ryan, CJ; Small, EJ | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL | 1 |
| Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S | 1 |
| Augustin, D; Böhmer, S; Du Bois, A; Erber, R; Gluz, O; Harbeck, N; Hartmann, A; Hoffmann, G; Huober, J; Jänicke, F; Kates, RE; Kiechle, M; Kreienberg, R; Kreipe, HH; Kuhn, W; Lisboa, B; Möbus, V; Mohrmann, S; Moustafa, Z; Nitz, U; Sattler, D; Scholz, M; Thomssen, C; Wallwiener, D; Weiss, E | 1 |
| Agarwal, N; Beer, TM; Bergman, AM; Bossi, A; Ciuleanu, TE; Drake, CG; Fizazi, K; Franke, FA; Gagnier, P; Gerritsen, WR; Hansen, S; Houede, N; Korbenfeld, E; Krainer, M; Kwon, ED; Liu, D; Logothetis, C; Mahammedi, H; Maio, M; McHenry, MB; Ng, S; Santos, R; Scher, HI; Sengeløv, L; Sundar, S; van den Eertwegh, AJ | 1 |
| Chevreau, C; De Mont-Serrat, H; Droz, JP; Kaiser, R; Medioni, J; Merger, M; Oudard, S; Stopfer, P | 1 |
| Han, KS; Hong, SJ | 1 |
| Alexandris, E; Arrieta, O; Bidoli, P; Cappuzzo, F; Ciuleanu, TE; Czyzewicz, G; Dakhil, S; Gans, S; Garon, EB; Goksel, T; Gorbunova, V; Grigorescu, A; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lewanski, CR; Orlov, SV; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Sashegyi, A; Syrigos, KN; Thomas, M; Yurasov, S | 1 |
| Balázs, G; Kovalszky, I; Losonczy, G; Moldvay, J; Pápay, J; Puskás, R | 1 |
| Allyon, J; Deplanque, G; Dufour-Lamartinie, JF; Elaidi, R; Ferrero, JM; Houillier, P; Lerest, C; Mackenzie, S; Maruani, G; Maurina, T; Medioni, J; Oudard, S; Raymond, E; Renaux, S; Rodier, JM | 1 |
| Azad, AA; Chi, KN; Eigl, BJ; Kollmannsberger, C; Murray, RN | 1 |
| Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL | 1 |
| Corcoran, C; O'Driscoll, L; Rani, S | 1 |
| Arrieta, O; Dorantes-Gallareta, Y; Flores-Estrada, D; Macedo-Pérez, EO; Mendoza-García, VO; Morales-Oyarvide, V | 1 |
| Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK | 1 |
| Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA | 1 |
| Antonuzzo, A; Biasco, E; Bocci, G; Danesi, R; Derosa, L; Di Desidero, T; Falcone, A; Farnesi, A; Fioravanti, A; Fontana, A; Francia, G; Galli, L; Marconcini, R; Orlandi, P | 1 |
| Alimonti, A; Catapano, C; Chen, JJ; Collado, M; D'Antuono, R; Da Silva-Alvarez, S; Di Mitri, D; Eisenberger, M; Garcia-Escudero, R; Grassi, F; Guccini, I; Jost, TR; Montani, E; Pinton, S; Sarti, M; Toso, A; Zhang, Z | 1 |
| Antonarakis, ES; Carducci, MA; Denmeade, SR; Eisenberger, MA; Nadal, R; Paller, CJ; Rahman, H; Schweizer, MT; Zhang, Z | 1 |
| Azuma, H; Cox, ME; Fazli, L; Ghaffari, M; Gleave, ME; Ibuki, N; Levitzki, A; Pandey, M; Reuveni, H | 1 |
| Hara, H; Itaya, N; Nutahara, K; Okegawa, T; Tambo, M | 1 |
| de Morrée, ES; de Ridder, CMA; de Wit, R; Kweldam, CF; Mathijssen, RHJ; van Soest, RJ; van Weerden, WM; Wiemer, EAC | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Gao, JF; Huang, XY; Jing, SF; Li, CD; Wang, DZ; Wei, H | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gaschler-Markefski, B; Gottfried, M; Griebsch, I; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Palmer, M; Reck, M; von Pawel, J | 1 |
| Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A | 1 |
| Heigener, D; Reck, M; Reinmuth, N | 1 |
| Agarwal, N; Agus, D; Bellmunt, J; Borgstein, N; Carcano, F; Cruz, FM; De Bono, J; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fountzilas, G; Jones, R; Lee, SY; Oudard, S; Petrylak, DP; Saad, F; Tejura, B; Ulys, A; Webb, IJ | 1 |
| Li, XN; Liu, DL; Qi, Y; Wu, K; Yang, Y; Zhang, CY; Zhao, J; Zhao, S; Zhou, XD; Zhu, DY | 1 |
| Beckett, LA; Lara, PN; Lo, EN; Pan, CX; Robles, D; Sands, JM; Suga, JM | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Ahn, MJ; Baas, P; Blumenschein, GR; Cadranel, J; De Pas, T; Dunphy, F; Hanna, NH; Jänne, PA; Kim, DW; Kim, JH; Kim, SW; Mazieres, J; Planchard, D; Puski, A; Rappold, E; Redhu, S; Smit, EF; Udud, K; Wu, FS | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Dhillon, S | 1 |
| Dai, XL; Feng, YZ; Han, ZB; Liu, YF; Qiu, J; Yang, YT | 1 |
| Chen, N; Chen, X; Chen, Z; Gong, J; Gui, H; Li, X; Liao, B; Liu, J; Liu, L; Liu, Z; Peng, Z; Shen, P; Wei, Q; Xu, M; Zeng, H; Zhang, P; Zhang, X; Zhao, T; Zhou, Q | 1 |
| Kamiya, N; Kawahara, T; Matsubara, N; Nishiyama, T; Satoh, T; Suzuki, H; Tabata, K; Takizawa, I; Ueda, Y; Uemura, H | 1 |
| Fizazi, K; Jenkins, C; Tannock, IF | 1 |
| Chopra, S; Rashid, P | 1 |
| Catino, A; De Ceglie, A; Galetta, D; Logroscino, A; Misino, A; Natalicchio, MI; Simone, G | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Armstrong, A; Ferrari, A; Hainsworth, J; Higano, CS; Hozak, RR; Hussain, M; Joshi, A; Kelly, WK; Liu, G; Rathkopf, D; Schwartz, JD; Yang, L | 1 |
| Bourhis, J; Bozec Le Moal, L; Dillies, AF; Fayette, J; Guigay, J; Henry, S; Kerger, JN; Machiels, JP; Pointreau, Y; Schilf, A; Sire, C; Tennevet, I; Zanetta, S | 1 |
| Arichi, N; Harada, Y; Hiraki, M; Mitsui, Y; Shiina, H; Yasumoto, H | 1 |
| Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G | 1 |
| Ahn, S; Byun, SS; Hong, SK; Jeong, SJ; Jo, JK; Kim, KB; Lee, S; Lee, SE | 1 |
| Han, WK; He, ZS; Huang, LH; Jin, J; Song, Y; Yang, KW; Yu, W; Zhou, LQ | 1 |
| Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Dickow, B; Fontana, J; Heath, E; Heilbrun, L; Land, S; Li, J; Shevrin, D; Smith, D; Stark, K; Stein, M; Vaishampayan, U | 1 |
| Altavilla, A; Bracarda, S; Carlini, P; Caserta, C; Chioni, A; De Angelis, V; Derosa, L; Felici, A; Galli, L; Hamzaj, A; Pastina, I; Rossi, M; Scali, S; Sisani, M | 1 |
| Crabb, S; Davda, R; Hughes, S; Jones, R; Payne, H; Troup, J | 1 |
| Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Armstrong, AJ; Fandi, A; Petrylak, DP; Pond, GR; Rosenthal, M; Sonpavde, G; Templeton, AJ; Tombal, B | 1 |
| Daga, H; Goto, K; Hattori, Y; Iwamoto, Y; Kaneda, H; Kawaguchi, T; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishimura, T; Oguri, T; Saka, H; Seto, T; Shukuya, T; Sugawara, S; Takahashi, T; Yamamoto, N; Yamanaka, T; Yokota, S | 1 |
| Dong, N; Lyerly, HK; Ren, J; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| de Boer, JP; de Jong, MA; Driessen, CM; Gelderblom, H; Kaanders, JH; Melchers, WJ; Rasch, CR; Tesselaar, ME; van der Graaf, WT; van Herpen, CM; Verbist, BM | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Choi, MK; Hwang, JE; Joung, JY; Kim, JE; Kim, YH; Lee, KH; Lee, SJ; Park, WS; Shin, SP | 1 |
| Bolenz, C; Fuxius, S; Heinrich, E; Müller, M; Schwartz, M; von Hardenberg, J; Weiß, C; Werner, T | 1 |
| Azuma, K; Daga, H; Hayashi, H; Hirashima, T; Kubo, A; Miyahara, E; Murakami, H; Nakagawa, K; Nakanishi, Y; Nogami, N; Okada, M; Okamoto, I; Saito, H; Sawa, T; Seto, T; Sugawara, S; Takeda, M; Urata, Y; Yamanaka, T; Yonesaka, K | 1 |
| Bruce, J; De Porre, P; Gonzalez, MD; Kheoh, T; Lim, EA; Maul, S; Nanus, DM; Peng, W; Petrylak, DP; Posadas, EM; Smit, JW; Tagawa, ST; Tran, N | 1 |
| Isogai, N; Iwasa, T; Nakagawa, K; Nishio, K; Sakai, K; Shimizu, T; Takahama, T; Takeda, M; Tanizaki, J; Tsurutani, J; Wada, Y; Watanabe, S | 1 |
| Hoshi, K; Hosoda, K; Katada, C; Katada, N; Koizumi, W; Mieno, H; Moriya, H; Watanabe, M; Yamashita, K | 1 |
| Jin, Z; Li, B; Li, H; Liu, C; Ou, X; Xu, Y; Zhang, Y; Zhou, H | 1 |
| Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG | 1 |
| Blumenthal, G; He, K; Kazandjian, D; Keegan, P; Libeg, M; Mushti, S; Pazdur, R; Suzman, DL | 1 |
| Gyawali, B; Iddawela, M; Koomulli-Parambil, S | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Agarwal, N; Alex, A; Heilbrun, ME; Parker, SJ; Pond, GR; Sonpavde, G | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Enatsu, S; Ferry, D; Hosomi, Y; Kasahara, K; Koue, T; Lee, P; Nakagawa, K; Nakamura, T; Nishio, M; Ohe, Y; Takahashi, T; Tamura, T; Yamada, K; Yamamoto, N; Yoh, K | 1 |
| Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S | 1 |
| Daga, H; Takeda, K | 1 |
| Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR | 1 |
| Büdi, L; Erfán, J; Győrfy, K; Hitre, E; Horváth, Z; Kahán, Z; Kocsis, J; Kószó, R; Landherr, L; Máhr, K; Pajkos, G; Pápai, Z; Sántha, D | 1 |
| Aziz, T; Chow, MJ; Cutz, JC; Jayasekera, D; Kapoor, A; Major, P; Tang, D; Wei, F; Wong, N; Yan, J; Zheng, M | 1 |
| Choi, HY; Il Seo, S; Jeon, HG; Jeon, SS; Jeong, BC; Kim, JH; Kwon, GY; Lee, HM; Lim, JE; Song, W | 1 |
| Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M | 1 |
| Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN | 1 |
| Abesamis-Tiambeng, ML; Akewanlop, C; Baczkowski, M; Baramidze, K; Barve, A; Bondarenko, I; Hernandez-Bronchud, M; Herson, J; Kothekar, M; Loganathan, S; Mamillapalli, G; Manikhas, A; Mukhametshina, G; Nemsadze, G; Parra, JD; Pennella, E; Ray, S; Rugo, HS; Sharma, R; Sriuranpong, V; Vynnychenko, I; Waller, CF; Yanez Ruiz, EP; Yuan, J | 1 |
| Cicero, G; De Luca, R; Dieli, F; Dispensa, N; Dorangricchia, P; Galvano, A; Lo Re, G; Serretta, V | 1 |
| Daniluk, J; Krawczyk, P; Milanowski, J; Mlak, R; Powrózek, T; Szczyrek, M; Szudy-Szczyrek, A; Wojas-Krawczyk, K; Zwolak, A | 1 |
| Fu, P; Li, Q; Wen, F; Yang, Y; Zhang, P | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Abdallah, K; Hamilton, RJ; Joshua, AM; Khoja, L; Pintilie, M; Pitcher, B | 1 |
| Atagi, S; Fujita, S; Hida, T; Kato, T; Masuda, N; Nakanishi, Y; Namba, Y; Sakai, H; Satouchi, M; Takahashi, M; Takeda, K; Tamura, T; Tanaka, H | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Ding, WQ; Gu, MM; Li, M; Li, S; Liu, B; Shang, ZF; Xiao, BB; Yu, L; Zhou, J; Zhou, PK; Zou, S | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Bastick, P; Briscoe, K; Gurney, H; Horvath, LG; Lin, HM; Mahon, KL; Mallesara, G; Marx, G; Spielman, C; Stockler, MR; Swarbrick, A | 1 |
| Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Choueiri, MB; Do, KA; Kim, J; Lee, YC; Lin, SH; Logothetis, CJ; Mathew, P; Navone, NM; Tu, SM; Wen, S; Ye, X; Yu-Lee, LY | 1 |
| Baselga, J; Prat, A | 1 |
| Bamias, A; Briasoulis, E; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karina, M; Koutras, A; Pavlidis, N; Pentheroudakis, G; Samantas, E; Samelis, G; Xiros, N | 1 |
| Barton, J; Burris, HA; Greco, FA; Infante, J; Jones, S; Patton, J; Shipley, D; Spigel, D; Thompson, D | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Biasco, G; Brandi, G; Danesi, R; de Rosa, F; Montini, GC | 1 |
| Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D | 1 |
| De Santis, M; Fink, E; Hobisch, A; Höltl, W; Krainer, M; Kramer, G; Marei, IC; Neumann, HJ; Rauchenwald, M; Reissigl, A; Schmeller, N; Stackl, W | 1 |
| Agarwal, A; Azabdaftari, G; Covic, L; Kaneider, NC; Kuliopulos, A; Lazarides, K; Sevigny, LM; Sharifi, S | 1 |
| Bonny, MA; Clausse, M; D'Hondt, L; Dopchie, C; Duck, L; Filleul, B; Honhon, B; Jousten, P; Kerger, J; Machiels, JP; Marcelis, L; Mazzeo, F; Moxhon, AM; Tombal, B; Verhoeven, D; Verschaeve, V | 1 |
| Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S | 1 |
| Beer, TM; Blanke, CD; Lopez, C; Mori, M; Stone, M; Todd, K | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Schneider, BJ; Smith, DW; Worden, FP; Wozniak, AJ | 1 |
| Kim, JH; Lee, CT; Lee, JS; Lee, KW; Lim, JH | 1 |
| Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X | 1 |
| Herbst, RS; Hong, WK; Kim, ES; Lee, JJ; Liu, D; Mauer, AM; Tran, HT; Vokes, EE; William, WN; Windt, P | 1 |
| Albanell, J; Bellmunt, J; Carles, J | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F | 1 |
| Hegele, A; Hofmann, R; Olbert, PJ; Schrader, AJ; Weil, C | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Cassileth, BR; Coleton, M; Deng, G; Guillen, S; Kris, MG; Rizvi, N; Vickers, A; Woo, D; Yeung, KS | 1 |
| Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S | 1 |
| Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tsakalaki, E | 1 |
| Heidenreich, A | 1 |
| Carr, R; Chi, KN; Ellard, SL; Kollmannsberger, C; Le, L; Michels, J; Murray, N; Tomlinson Guns, ES | 1 |
| Ahn, YM; Kang, EM; Kim, BS; Kim, HJ; Kim, JH; Kim, TG; Lee, BU; Lee, HJ; Lim, BH; Nam, SH; Roh, YH; Seo, JW | 1 |
| Gkini, E; Gkiozos, I; Katirtzoglou, N; Kotteas, E; Makrilia, N; Ralli, M; Syrigos, K; Tourkantonis, I | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Akiyama, F; Domoto, K; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miyagi, Y; Ogiya, A; Osako, T; Takahashi, S | 1 |
| Balashova, OI; Bogdanova, NV; Bondarenko, IN; Chatikhine, VA; Makhson, AN; Manikhas, GM; Oliynychenko, GP; Rackoff, WR; Semiglazov, VF; Sparano, JA; Tjulandin, SA; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Ando, M; Eguchi, K; Fujiwara, Y; Hozumi, Y; Inoue, K; Masuda, N; Miura, S; Mizutani, M; Nakagami, K; Noguchi, S; Ohashi, Y; Saito, M; Sano, M; Shinkai, T; Tsukamoto, F; Watanabe, T | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Beltran, P; Brammer, C; Jansen, JP; Parthan, A; Posner, MR | 1 |
| Gemma, A; Hino, M; Kudoh, S; Nagao, K; Niitani, H; Tada, Y; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Crisci, A; Della Melina, A; Molinara, E; Neri, B; Nicitat, G; Pantaleo, P; Rangan, S; Raugei, A; Villari, D | 1 |
| Borsellino, N; Carrozza, F; Caruso M, M; Cinieri, S; Colucci, G; Ferraù, F; Galetta, D; Gebbia, V; Leo, S; Lorusso, V; Mancarella, S; Mancuso, G; Palomba, G; Riccardi, F | 1 |
| Fang, Q; Ou, W; Sun, HB; Wang, SY; Yang, H; Zhang, BB | 1 |
| Drudi, F; Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Hou, XH; Jiang, L; Tang, LF; Wang, DF; Wang, DY; Xie, Z; Zhao, HD; Zhu, ZH | 1 |
| Yu, JM; Yu, YH; Zhang, Y | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Altintas, S; Dyck, J; Huizing, MT; Schrijvers, D; Specenier, PM; Van Den Brande, J; Van Den Weyngaert, D; Van Laer, C; Vermorken, JB | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Blohmer, JU; Friese, K; Hilfrich, J; Kleine-Tebbe, A; Koelbl, H; Kuemmel, S; Lichtenegger, W; Morack, G; Schmid, P; Sommer, H; Wischnewsky, MB | 1 |
| Choi, DR; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, JA; Park, YI; Shin, HC; Song, HH; Zang, DY | 1 |
| Arellano, J; Asukai, Y; Camps, C; Cassinello, A; Dilla, T; Sacristán, JA; Taipale, K; Valladares, A; Wood, E | 1 |
| Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
| Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME | 1 |
| Aitini, E; Baconnet, B; Barbato, A; Bighin, C; Colucci, G; Crinò, L; Del Mastro, L; Garrone, O; Mansutti, M; Marini, G; Olmeo, N; Paccagnella, A; Puglisi, F; Venturini, M | 1 |
| Ando, Y; Arima, H; Fujimoto, Y; Imai, T; Inada, M; Kamei, S; Kawada, K; Kikumori, T; Kitagawa, K; Mitsuma, A; Sawaki, M | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Beuzeboc, P; Eymard, JC; Ferrero, JM; Gravis, G; Joly, F; Krakowski, I; Oudard, S; Priou, F; Theodore, C; Thill, L; Zannetti, A | 1 |
| Bauerfeind, P; Bertschinger, P; Binek, J; Brauchli, P; Frossard, JL; Jost, C; Knuchel, J; Metzger, U; Meyenberger, C; Ruhstaller, T; Schuller, JC; Werth, B | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Beretov, J; Chen, H; Cozzi, PJ; Delprado, WJ; Hao, J; Li, Y; Madigan, MC; Russell, PJ; Xiao, W | 1 |
| Andreasson, I; Boér, K; Láng, I; Llombart-Cussac, A; Murray, E; Pover, GM; Sanders, N; Vivanco, GL | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Bernier, J; Betka, J; Bottomley, A; Coens, C; Degardin, M; Jelic, S; Mauer, ME; Mesia, R; Preiss, JH; Remenar, E; Stewart, JS; van den Weyngaert, D; van Herpen, CM; Vermorken, JB | 1 |
| Breithaupt, K; Thuss-Patience, PC | 1 |
| Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L | 1 |
| Casado, MÁ; Cortés, J; Frías, C; Oyagüez, I; Seguí, MÁ | 1 |
| Berglund, A; Byström, P; Einarsson, R; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Nabhan, C | 1 |
| Costa, J; Henderson, R; Hoppe, BS; Li, Z; Marcus, RB; Mendenhall, NP; Mendenhall, WM; Morris, CG; Nichols, RC; Williams, CR | 1 |
| Georgoulias, V; Kaklamanis, L; Lagoudaki, E; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Tryfonidis, K; Trypaki, M; Tsaroucha, E | 1 |
| Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH | 1 |
| Fujiwara, H; Furutani, A; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Shiozaki, A; Sonoyama, T; Todo, M; Umehara, S; Yoneda, M | 1 |
| Cao, X; Guo, Y; Huang, H; Huang, X; Huang, Y; Lan, C; Liu, J; Wan, T; Zhang, Y | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S | 1 |
| Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R | 1 |
| Ashcroft, L; Blackhall, F; Burt, P; Califano, R; Chittalia, A; Faivre-Finn, C; Griffiths, R; Harris, M; Lee, L; Lorigan, P; Taylor, P; Thatcher, N | 1 |
| Duman, BB; Ercolak, V; Günaldi, M; Kara, IO | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Anantha, M; Bally, MB; Kalra, J; Masin, D; Osooly, M; Strut, D; Warburton, C; Waterhouse, D; Yan, H; Yang, YJ | 1 |
| Fujiwara, K; Kigawa, J; Kitada, F; Nagao, S; Nishimura, R; Takekida, S; Terakawa, N; Yamaguchi, S; Yoshida, N | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Blasco, A; Camps, C; Jantus-Lewintre, E; Rosell, R; Sanchez, JJ; Sanmartín, E; Sirera, R; Tarón, M | 1 |
| Akiyama, H; Endo, I; Fujii, S; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Nagano, Y; Ono, HA; Takagawa, R | 1 |
| Danno, K; Imaoka, S; Iwazawa, T; Kagara, N; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H | 1 |
| Sartor, AO | 1 |
| Dai, H; Liu, JW; Yan, D | 1 |
| Aita, M; Belvedere, O; Dal Bello, MG; Defferrari, C; Fasola, G; Follador, A; Gaiardo, M; Grossi, F; Meduri, S; Merlo, V; Rossetto, C; Sibau, AM | 1 |
| Cicero, G; De Luca, R | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Choi, SY; Choi, Y; Chung, IY; Kang, E; Kim, EJ; Kim, IA; Kim, JH; Kim, SW; Kim, YJ; Lee, HE; Park, SY; Ryu, HS | 1 |
| Bontenbal, M; Bos, MM; Braun, HJ; Creemers, GJ; Erdkamp, FL; Hamberg, P; Klijn, JG; Loosveld, OJ; Muller, EW; Portielje, JE; Pruijt, JF; Schmitz, PI; Seynaeve, C; Smit, WM; Stouthard, JM; van Deijk, GA; van der Stelt-Frissen, IN | 1 |
| Rexer, H | 3 |
| Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Pagliaro, LC; Pettaway, CA; Pisters, LL; Troncoso, P; Tzelepi, V; Wen, S | 1 |
| Chen, JS; Chen, PT; Chen, YY; Hsu, HC; Huang, JS; Lin, YC; Shen, WC; Wang, HM; Yeh, KY | 1 |
| Harrington, JA; Jones, RJ | 1 |
| Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohashi, Y; Sato, N; Toi, M; Tsuda, H; Yamamoto, N | 1 |
| Aydiner, A; Dilege, S; Eralp, Y; Oral, EN; Saglam, EK; Sen, F; Tas, F; Toker, A | 1 |
| Bonetti, A; Durante, E; Mercanti, A; Piacentini, P; Trolese, A | 1 |
| Hongo, F; Iwata, T; Kamoi, K; Kawauchi, A; Miki, T; Okihara, K; Takaha, N; Takeuchi, I; Ueda, T; Yamada, T; Yano, K | 1 |
| Arai, G; Itoh, K; Matsueda, S; Matsuoka, K; Moriya, F; Noguchi, M; Sasada, T; Suekane, S; Yamada, A | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Adenis, A; Baey, C; Bennouna, J; Berille, J; Celier, P; Ducreux, M; Mornex, F; Oberic, L; Peiffert, D; Pignon, JP; Viret, F; Ychou, M | 1 |
| Alexandre, J; Bousquet, G; de Mont-Serrat, H; Faivre, S; Goldwasser, F; Kaiser, R; Le Tourneau, C; Misset, JL; Raymond, E | 1 |
| Swartman, B | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Belfiglio, M; Fanizza, C; Ficorella, C; Iacobelli, S; Natoli, C; Tinari, N | 1 |
| Bougnoux, P; Champeroux, P; Chevalier, S; Goupille, C; Kornfeld, S; Lebeau, J; Mahéo, K; Martel, E; Maurin, A; Pinet, A; Richard, S; Tranquart, F; Vibet, S | 1 |
| Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW | 1 |
| Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY | 1 |
| Harbeck, N | 1 |
| Blenc, AM; Boxwala, I; Chisti, MM; Jaiyesimi, I; Micale, MA; Muslimani, A | 1 |
| Treshalina, EM; Yakunina, MN | 1 |
| Dawson, N; Moul, JW | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Brugnara, S; Caffo, O; Caldara, A; di Pasquale, MC; Ferro, A; Frisinghelli, M; Galligioni, E; Murgia, V; Pappagallo, G; Russo, LM; Soini, B; Valduga, F; Veccia, A | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Herchenhorn, D; Maluf, FC; Smaletz, O | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Antonarakis, ES; Carducci, MA; De Marzo, AM; Eisenberger, MA; Fedor, HL; Gurel, B; Hicks, JL; Keizman, D; Lotan, TL; Zhang, Z | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H | 1 |
| Attard, G; Baikady, B; Bianchini, D; de Bono, J; Hunt, J; Maier, G; Mezynski, J; Mulick Cassidy, A; Olmos, D; Pezaro, C; Reid, AHM; Sandhu, S; Sarvadikar, A; Sheridan, E; Thompson, E; Zivi, A | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Nakagawa, K; Nakanishi, Y; Okamoto, I; Takeda, M; Yamanaka, T | 1 |
| Alexandris, E; Cao, D; Garon, EB; John, WJ; Perol, M; Yurasov, S | 1 |
| Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Kübler, H; Maurer, T; Nawroth, R; Retz, M; Thalgott, M; Wolf, P | 1 |
| Bhowmick, NA; Chu, CY; Chung, LW; Fernandez, A; Fritz, G; Jackson, RS; Kitada, S; Pellecchia, M; Placzek, W; Reed, JC; Stebbins, J; Wei, J; Ziaee, S | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, DE; Na, KJ; Nam, TK; Shim, HJ | 1 |
| Benson, MC; Bonal, DM; Castillo-Martin, M; Charytonowicz, E; Cordon-Cardo, C; de la Iglesia-Vicente, J; Domingo-Domenech, J; Gladoun, N; Petrylak, DP; Quinn, SA; Rodriguez-Barrueco, R; Rodriguez-Bravo, V; Silva, JM; Vidal, SJ | 1 |
| Berdah, JF; Bondiau, PY; Castelnau, O; Chamorey, E; De Surmont Salasc, B; Michel, C; Mouroux, J; Otto, J; Pop, D; Poudenx, M; Pourel, N; Tessier, E; Venissac, N | 1 |
| Alifrangis, C; Coombes, RC; Emson, M; Mackie, D; Palmieri, C; Shipway, D; Tat, T; Watson, V | 1 |
| Penson, DF; Resnick, MJ | 1 |
| Cheng, HH; Lin, DW; Yu, EY | 1 |
| Antonarakis, ES; Eisenberger, MA | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Eidelman, O; Kallakury, BV; Kasid, UN; Kumar, D; Luta, G; Mewani, RR; Pollard, HB; Ross, JS; Sakabe, I; Sheehan, CE; Sreenath, TL; Srivastava, M; Srivastava, S; Starr, J; Yadavalli, S; Zhang, C | 1 |
| Cho, KW; Choi, C; Choi, SH; Choi, Y; Eun, SJ; Kim, HJ; Kim, HS; Lee, KM; Moon, WK; Noh, DY; Whangbo, TK; Woo, J; Yi, YJ | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Ernst, DS | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Belani, CP; Langer, C | 1 |
| Abratt, RP; Krofta, K; Mattson, KV; ten Velde, G | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Aihara, T; Hiraki, S; Horikoshi, N; Inaji, H; Itoh, K; Katsumata, N; Noguchi, S; Sasaki, Y; Sonoo, H; Tabei, T; Takatsuka, Y; Watanabe, T | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Roth, AD | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 2 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Bories, E; Braud, AC; Camerlo, J; Dubois, JB; Genre, D; Giovannini, M; Gonçalves, A; Gravis, G; Magnin, V; Maraninchi, D; Moutardier, V; Viens, P; Viret, F; Ychou, M | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Busby, E; Carey, DE; Marques, MB; Reynolds, RE; Robert, F | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bamias, C; Deliveliotis, C; Dimopoulos, MA; Gika, D; Kalofonos, C; Kosmidis, P; Kourousis, C; Koutras, A; Mitropoulos, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Xiros, N; Zervas, A | 1 |
| Godley, PA; Halabi, S; Kelly, WK; Oh, WK; Small, EJ; Vogelzang, NJ; Werner, C | 1 |
| Brechot, JM; Breton, JL; Clouet, P; Debieuvre, D; Depierre, A; Ducolone, A; Lebeau, B; Lemarie, E; Milleron, B; Moro-Sibilot, D; Pujol, JL; Quoix, E; Vaylet, F; Vergnenegre, A; Zalcman, G | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Azli, N; Buzzi, F; Capri, G; Cresta, S; Cuna, GR; Frevola, L; Gianni, L; Grasselli, G; Jirillo, A; Lelli, G; Mansutti, M; Martoni, A; Murawsky, M; Sguotti, C; Tarenzi, E; Terzoli, E | 1 |
| Julka, PK; Mukhopadhyay, P; Rath, GK; Sharma, DN | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, K; Lee, MH; Lee, SH; Lee, SI; Park, J; Park, JO; Park, K; Park, YS | 1 |
| Agelidou, A; Agelidou, M; Alegakis, A; Ardavanis, A; Chandrinos, V; Christofilakis, C; Georgoulias, V; Kouroussis, C; Papakotoulas, P; Polyzos, A; Samaras, N; Syrigos, K; Toumbis, M; Tsaroucha, E; Ziras, N | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| España, L; Gu, B; Méndez, O; Sierra, A; Torregrosa, A | 1 |
| Eguchi, K; Inoue, F; Nakamura, H; Semba, H; Seto, T; Takeda, K; Takezako, Y | 1 |
| Castellana, MA; De Sio, L; Fanelli, M; Ferraù, F; Gasparini, G; Gattuso, D; Lo Vullo, S; Lorusso, V; Mariani, L; Morabito, A; Priolo, D; Sarmiento, R; Stani, SC; Vitale, S | 1 |
| Herzog, TJ | 1 |
| Caillaud, D; Clary, C; Clouet, P; Coudert, B; Couteau, C; D'Arlhac, M; Dabouis, G; Douillard, JY; Gervais, R; Le Groumellec, A; Maury, B; Monnier, A; Mornet, M; Rivière, A; Spaeth, D | 1 |
| Braun, D; Breton, JL; Clouet, P; Debieuvre, D; Ducolone, A; Gervais, R; Lebeau, B; Pujol, JL; Quoix, E; Tredaniel, J; Vaylet, F | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Arizcun, A; Cruz, JJ; Fonseca, E; Gómez-Bernal, A; Martín, G; Martín, T; Olaverri, A; Rodríguez, CA; Sánchez, P | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Casorzo, L; Montemurro, F; Redana, S; Risio, M | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Bang, SM; Cho, EK; Lee, JH; Lee, YD; Park, SH; Shin, DB | 1 |
| Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| George, DJ; Moore, CN | 1 |
| Hamel, K; Hamolsky, D; Melisko, M; Topp, KS; Wampler, MA | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| de Bree, E; Panagiotidis, J; Romanos, J; Tsetis, D; Tsiftsis, DD; Varthalitis, Y; Volalakis, E | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Blomqvist, C; Larsson, R; Nygren, P; Villman, K | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| George, DJ; Oh, WK; Tay, MH | 1 |
| Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P | 1 |
| Baek, JH; Jung, HY; Kim, DH; Kim, JG; Kim, TB; Lee, KB; Park, JY; Sohn, SK; Sung, WJ; Yu, W | 1 |
| Horai, T; Matsuda, M; Morikawa, A; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Tabata, D | 1 |
| Ahn, JH; Kang, YK; Kim, SB; Kun Kim, W; Lee, JS; Sohn, HJ | 1 |
| Beer, TM; Garzotto, M; Ryan, CW; Tiffany, NM; Wersinger, EM | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Budd, GT; Erban, J; Hutchins, L; Jones, SE; Laufman, L; Lower, E; Mennel, R; Meyers, ML; Olsen, S; Overmoyer, B; Pritchard, KI; Ravdin, PM; Richards, D; Sundaram, S; Urba, WJ | 1 |
| Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E | 1 |
| Addo, FK; Cole, JT; Fitch, TR; Flynn, PJ; Ingle, JN; Mailliard, JA; Perez, EA; Suman, VJ; Veeder, MH; Walsh, DJ | 1 |
| Edelman, MJ | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Almenar, D; Batista, N; Blanco, R; Blasco, A; Camps, C; Carrato, A; Diz, P; Felip, E; Galán, A; Girón, CG; Gómez, RG; González, JL; Isla, D; Jiménez, A; López, M; Maestu, I; Massuti, B; Provencio, M; Rosell, R; Viñolas, N | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| André, T; Bennamoun, M; Carola, E; Flesch, M; Gamelin, E; Louvet, C; Nguyen, S; Rebischung, C; Van Ongeval, J; Ychou, M | 1 |
| Kollmannsberger, C; Michels, J; Montemurro, T; Murray, N; Nguyen Chi, K | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK | 1 |
| Doliny, P; Gomez-Fernandez, C; Hurley, J; Pauletti, G; Pegram, MD; Powell, JE; Reis, I; Silva, O; Slamon, DJ; Velez, P | 1 |
| Burgess, EF; Roth, BJ | 1 |
| Alcaide García, J; Alés Díaz, I; Benavides Orgaz, M; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Villar Chamorro, E | 1 |
| Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T | 1 |
| Allen, J; Chen, HX; Dodley, A; Eckhardt, SG; Elias, AD; Hauger, M; Kelbick, NT; Kendra, K; Morrow, M; Ramaswamy, B; Rhoades, C; Shapiro, CL | 1 |
| Ahn, JS; Im, YH; Kang, JH; Kang, WK; Lee, J; Lee, SI; Lim, HY; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Gotoh, M; Hirabayashi, N; Ninomiya, M; Nishiyama, M; Sakamoto, J; Sato, Y; Takakura, N; Takiyama, W; Terashima, M; Todo, S; Yoshida, K | 1 |
| Agostara, B; Gebbia, V; Laudani, A; Leonardi, V; Pepe, A; Savio, G; Scianna, C | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Goguen, L; Haddad, R; Li, Y; Norris, CM; O'Donnell, L; Posner, M; Sullivan, C; Tishler, R; Wirth, L | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Farfan, N; Hamilton-Nelson, K; Lopes, G; Negret, LM; Raez, LE; Rocha-Lima, C; Roman, E; Rosado, MF; Santos, ES; Silva, O; Tolba, K | 1 |
| Aurilio, G; Carlomagno, C; Catalano, G; Ciardiello, F; De Placido, S; De Vita, F; Galizia, G; Lieto, E; Martinelli, E; Orditura, M; Vecchione, L | 1 |
| Czejka, M; Hilbe, W; Hochegger, K; Lhotta, K; Mayer, G | 1 |
| Albanell, J; Bosch, M; Campás, C; Codony-Servat, J; Dang, L; Domingo-Domenech, J; Filella, X; Gascon, P; Mellado, B; Montagut, C; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, M | 1 |
| Barrett-Lee, P; Grieve, R; Houston, S; Howell, A; Johnston, S; Leonard, R; Malinovszky, K; O'Reilly, S; Verrill, M; Wardley, A | 1 |
| Albain, KS; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Kelly, K; Lara, PN; Livingston, R | 1 |
| Sweeney, CJ | 1 |
| Berghmans, T; Paesmans, M; Sculier, JP | 1 |
| Asada, M; Fuji, H; Inoue, D; Kanda, A; Kaneta, T; Kondo, T; Nakayama, K; Okinaga, S; Sasaki, H; Sasaki, T; Suzuki, S; Suzuki, T; Takai, Y; Watanabe, M; Yamanda, S; Yamaya, M; Yanagihara, K; Yasuda, H; Yoshida, M; Zayasu, K | 1 |
| Bubley, GJ; Ernstoff, MS; Morganstern, DE; Regan, MM; Taplin, ME; Walsh, W; Xie, W | 1 |
| Abdel-Khalek, Z; Bitar, N; Charafeddine, M; Chehal, A; Dandashi, A; Dheiny, M; El-Saghir, NS; Jalloul, R; Khalifeh, MJ; Otrock, ZK; Shamseddine, AI; Wehbeh, M; Yassine, HR | 1 |
| Francini, E; Francini, G; Manganelli, A; Paolelli, L; Petrioli, R; Salvestrini, F | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Magee, CC; Mendez, GP; Rennke, HG; Schlondorff, JS | 1 |
| Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Chang, HM; Chun, YJ; Kang, YK; Kim, BS; Kim, M; Kim, TW; Lee, JL; Lee, JS; Oh, ST; Ryu, MH; Yook, JH | 1 |
| Bueno Muiño, C; Díaz-Rubio, E; García Miralles, N; García-Sáenz, JA; Martín, M; Puente Vázquez, J; Sánchez-Pernaute, A; Sastre Valera, J | 1 |
| Barbanti, G; De Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A | 1 |
| Kovel, S; Sella, A; Skoneczna, I; Sternberg, C; Yarom, N | 1 |
| Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N | 1 |
| Blasinska-Morawiec, M; Bonneterre, J; Campone, M; Chatelut, E; Deporte-Fety, R; Douville, I; Ecochard, L; Koralewski, P; Leger, F; Longerey, B | 1 |
| Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G | 1 |
| Beer, TM; Dreicer, R; Fehrenbacher, L; Hannah, AL; Higano, CS; Hudes, G; Picus, J; Rarick, M; Saleh, M | 1 |
| Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V | 1 |
| Haberl, C; Heinemann, V; Hentrich, M; Lordick, F; Lorenzen, S; Peschel, C; Roethling, N; Schuster, T; Seroneit, T | 1 |
| Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Alfaro, J; Carles, J; Catalan, G; Domenech, M; Font, A; Gallardo, E; Gonzalez Del Alba, A; González-Larriba, JL; Lianes, P; Mellado, B; Nogué, M; Tello, JM | 1 |
| Alcaraz, A; Codony, J; Domingo-Domenech, J; Fernandez, E; Fernandez, PL; Filella, X; Gascon, P; Martinez-Fernandez, A; Mellado, B; Molina, R | 1 |
| Attard, G; Blagden, SP; de Bono, JS; de Jonge, M; Fong, PC; Kitzen, J; Pronk, LC; Verweij, J; Zhi, J; Zugmaier, G | 1 |
| Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N | 1 |
| Akmansu, M; Benekli, M; Bora, H; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Pak, Y; Uner, A; Unsal, D; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Beer, TM; Bubley, GJ; Huang, J; Jacobus, S; Oh, WK; Ross, RW; Ryan, CW; Taplin, ME | 1 |
| Ploner, F | 1 |
| Ferrell, B; Leong, L; Lowe, T | 1 |
| Charoentum, C; Chewasakulyong, B; Euathrongchit, J; Munprakan, S; Sorraritchingchai, S; Thongprasert, S | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| de Wit, R | 1 |
| Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS | 1 |
| Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M | 1 |
| Lee, R; Leighl, NB; Loreto, M; Ng, R | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Ardavanis, A; Baziotis, N; Garoufali, A; Kountourakis, P; Kyriakou, F; Malliou, S; Mantzaris, I; Rigatos, G; Scorilas, A; Yiotis, I | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| Barter, C; Berille, J; Bishop, J; Bougan, N; Friedlander, M; James, R; Loret, C; McKeage, M; Millward, M; Rischin, D; Toner, G; Zalcberg, J; Zimet, A | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J | 1 |
| Brown, RE; Hutton, J | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Dranitsaris, G; Leung, PP; Oza, AM; Puodziunas, A; Tannock, IF | 1 |
| Mattson, K | 1 |
| Gleave, ME; Goldie, J; Miayake, H; Nelson, C; Tolcher, A | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Buesa, J; Coleman, R; di Paola, ED; Judson, IR; Lee, SM; Ruka, W; Seynaeve, C; Tonelli, D; van Glabbeke, M; van Hoessel, R; Verweij, J | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Crawford, J; DeVore, R; Dunphy, F; Fossella, FV; Gamza, F; Gandara, D; Hammershaimb, L; Kalman, L; Karp, D; Kerr, RN; Kim, Y; Kris, M; Lee, JS; Miller, V; Moore, M; Natale, RR; Vokes, E | 1 |
| Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR | 1 |
| Coleman, RE; Eggleton, SP; Howell, A; Maling, SJ; Miles, DW | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Sarmonis, G; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Fossella, FV | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Pagani, O; Sessa, C | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Albain, KS; Clark, JI; Fisher, S; Hantel, A; Kancharla, K; Millbrandt, L; Panganiban, J; Qamar, R | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Sparano, JA | 1 |
| Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Moore-Cooper, S; Sinibaldi, VJ; Zahurak, M | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
60 review(s) available for docetaxel anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design | 2021 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Topics: Androgen Antagonists; Combined Modality Therapy; Disease Progression; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung; Lung Neoplasms; Patient Selection; Ramucirumab; Time Factors | 2019 |
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Humans; Palliative Care; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Expert Testimony; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids | 2013 |
Current, new and novel therapy for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroids; Taxoids | 2015 |
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor A | 2015 |
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Standard of Care; Taxoids | 2015 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids | 2016 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Evidence-Based Medicine; Health Status; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Patient Selection; Population Surveillance; Prednisone; Prostatic Neoplasms; Taxoids; Tumor Burden; Uncertainty | 2017 |
Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Ramucirumab; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
[Metastatic gastric cancer: does second-line chemotherapy make sense?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retreatment; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Mixed Tumor, Mullerian; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Salpingectomy; Taxoids; Tomography, X-Ray Computed | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Treatment Outcome | 2011 |
Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Docetaxel; Hormones; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids | 2011 |
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids | 2012 |
Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Survival; Taxoids | 2012 |
Castration-resistant prostate cancer: systemic therapy in 2012.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Advanced clinical states in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Cancer Vaccines; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
The role of chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.
Topics: Activities of Daily Living; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diabetes Mellitus, Type 1; Disease Progression; Docetaxel; Exercise Therapy; Female; Hand Strength; Humans; Middle Aged; Nurse's Role; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Team; Peripheral Nervous System Diseases; Quality of Life; Severity of Illness Index; Taxoids | 2005 |
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Topics: Androgens; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Taxoids | 2006 |
Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Humans; Male; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids | 2007 |
Role of gemcitabine in metastatic breast cancer patients: a short review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
[NSCLC: update on second line therapy following ASCO 2007].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids | 2007 |
Quality-of-life issues in the management of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2007 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nomograms; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids | 2008 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Health Status; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
295 trial(s) available for docetaxel anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Disease Progression; Docetaxel; Humans; Kallikreins; Lycopene; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Time Factors | 2021 |
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2022 |
Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; India; Male; Mandible; Mandibular Osteotomy; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Progression-Free Survival; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tumor Burden | 2022 |
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed | 2022 |
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Topics: Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Disease Progression; Docetaxel; Humans; Lung Neoplasms | 2022 |
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2023 |
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
Topics: Anilides; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyridines; Retrospective Studies; Risk Factors; Survival Rate | 2020 |
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies | 2019 |
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Ramucirumab | 2020 |
Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Docetaxel; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Ramucirumab | 2020 |
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Topics: Aged; Alleles; Androgen Antagonists; Disease Progression; Disease-Free Survival; Docetaxel; Genotype; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Progesterone Reductase; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid Isomerases; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Progression-Free Survival; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; United States | 2020 |
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Neoplasm Grading; Prognosis; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Testosterone; Tumor Burden | 2020 |
CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Body Composition; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prospective Studies; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Psoas Muscles; Subcutaneous Fat; Tomography, X-Ray Computed | 2021 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom | 2021 |
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Curcumin; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Male; Medical Futility; Medication Adherence; Middle Aged; Placebos; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tubulin Modulators; Tumor Burden | 2021 |
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Taxoids; Treatment Outcome | 2017 |
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; France; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prostatic Neoplasms; Quality-Adjusted Life Years; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2017 |
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2017 |
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Topics: Adult; Aged; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome; Young Adult | 2017 |
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Postoperative Period; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Rate; Watchful Waiting | 2018 |
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome | 2018 |
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Feasibility Studies; Female; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; No-Observed-Adverse-Effect Level; Treatment Outcome | 2018 |
Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies | 2018 |
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2018 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2019 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pantoprazole; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Follow-Up Studies; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Survival | 2019 |
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Preliminary Data; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retreatment; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Steroid Hydroxylases; Survival Rate; Taxoids; Treatment Outcome; Vitamin D3 24-Hydroxylase | 2013 |
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Failure | 2013 |
Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; International Agencies; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2013 |
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Follow-Up Studies; Humans; International Agencies; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Time Factors | 2013 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Penile Neoplasms; Survival Analysis; Taxoids; United Kingdom | 2013 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dasatinib; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Taxoids; Thiazoles; Treatment Failure | 2013 |
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Severity of Illness Index; Taxoids; Treatment Failure; United States | 2013 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Endostatins; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies; Remission Induction; Taxoids | 2013 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2014 |
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2014 |
GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Taxoids | 2014 |
Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids | 2014 |
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Taxoids; Treatment Outcome; Young Adult | 2014 |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Docetaxel; Double-Blind Method; Humans; Ipilimumab; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tubulin Modulators | 2014 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Platinum; Quality of Life; Ramucirumab; Survival Rate; Taxoids | 2014 |
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Calcitriol; Taxoids; Treatment Outcome | 2014 |
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure | 2014 |
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Administration, Metronomic; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Double-Blind Method; Health Status; Humans; Indoles; Lung Neoplasms; Placebos; Quality of Life; Self Report; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2015 |
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2015 |
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy:
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Naphthalenes; Neoplasm Grading; North America; Odds Ratio; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Taxoids; Time Factors; Treatment Outcome | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Ramucirumab; Taxoids; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Everolimus; Humans; Male; Neoplastic Cells, Circulating; Phosphorylation; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2015 |
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2B6; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Genotype; Humans; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Taxoids; Thiotepa | 2015 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Netherlands; Radiotherapy Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Taxoids | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Epidemiologic Methods; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Taxoids; Treatment Outcome | 2016 |
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Programmed Cell Death 1 Receptor; Taxoids; United States; United States Food and Drug Administration | 2016 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Ramucirumab; Retreatment; Risk Factors; Taxoids; Treatment Outcome | 2016 |
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tetrahydronaphthalenes; Triple Negative Breast Neoplasms; Valine; Vomiting | 2017 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Analysis; Taxoids; Therapeutic Equipoise; Time Factors; Trastuzumab | 2017 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Risk Factors; Smoking; Taxoids; Tomography, X-Ray Computed; Tubulin Modulators | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Cohort Studies; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Survival Rate; Taxoids | 2017 |
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thionucleotides | 2017 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Greece; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Outpatients; Palliative Care; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2008 |
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Topotecan; Treatment Outcome | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Belgium; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2008 |
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2008 |
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcitriol; Calcium Channel Agonists; Calcium, Dietary; Disease Progression; Docetaxel; Drug Therapy, Combination; Fatigue; Female; Humans; Hyperglycemia; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pyrazoles; Salvage Therapy; Sulfonamides; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Severity of Illness Index; Survival Analysis; Taxoids | 2008 |
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2009 |
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2009 |
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Survival Rate; Taxoids | 2009 |
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Astragalus propinquus; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Interactions; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Plant Extracts; Survival Rate; Taxoids | 2009 |
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prostatic Neoplasms; Sulfonamides; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Taxoids | 2010 |
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Taxoids; Time Factors | 2009 |
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Markov Chains; Neoadjuvant Therapy; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2009 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Survival Analysis; Taxoids; Tegafur | 2010 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Taxoids | 2010 |
Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2009 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival; Taxoids; Time Factors; Treatment Outcome | 2010 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxins; Disease Progression; Docetaxel; Doxorubicin; Female; Heart; Humans; Kaplan-Meier Estimate; Liposomes; Middle Aged; Neoplasm Metastasis; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2010 |
The feasibility study of docetaxel in patients with anaplastic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Taxoids; Thyroid Neoplasms | 2010 |
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Therapy, Combination; Endosonography; Esophageal Neoplasms; Esophagus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Interactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Europe; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Patient Selection; Piperidines; Placebos; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; South Africa; Taiwan; Taxoids; Time Factors; Treatment Outcome | 2012 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Health Status; Humans; Quality of Life; Taxoids; Time Factors; Treatment Outcome | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Neutropenia; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Blood Chemical Analysis; Camptothecin; Disease Progression; Docetaxel; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Taxoids; Upper Gastrointestinal Tract | 2010 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure | 2011 |
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Quality of Life; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Patient Selection; Salvage Therapy; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2011 |
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Research Design; Taxoids; Treatment Outcome | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast c
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Germany; Humans; Male; Oligonucleotides, Antisense; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thionucleotides | 2011 |
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Topics: Adenocarcinoma; Adult; Aged; Androgens; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Combined Modality Therapy; Cystectomy; Disease Progression; Docetaxel; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neoplastic Stem Cells; Neovascularization, Physiologic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Signal Transduction; Taxoids; Time Factors | 2011 |
A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Taxoids; Treatment Outcome; Up-Regulation | 2011 |
Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Cytokines; Disease Progression; Docetaxel; Humans; Immunity, Humoral; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Precision Medicine; Prospective Studies; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2012 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2011 |
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2012 |
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Taxoids | 2012 |
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Humans; Lung Neoplasms; Ramucirumab; Research Design; Survival Analysis; Taxoids | 2012 |
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy, Conformal; Survival Rate; Taxoids | 2012 |
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Period; Safety; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
European experience of docetaxel and cisplatin in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel and radiotherapy and pancreatic cancer.
Topics: Adenocarcinoma; Aged; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Taxoids; Time Factors | 2003 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Enoxaparin; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2004 |
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Estramustine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Safety; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2004 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Survival Rate; Taxoids; Time Factors | 2004 |
Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; India; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Palliative Care; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2005 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2005 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2005 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Taxoids; Treatment Outcome | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2005 |
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2006 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2006 |
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2006 |
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome | 2006 |
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Palliative Care; Stomach Neoplasms; Taxoids; Vomiting | 2007 |
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2006 |
[Start of a new Working Group on Urological Oncology (AUO) study of prostate cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Germany; Humans; Male; Middle Aged; Prostatic Neoplasms; Retreatment; Taxoids | 2005 |
Treatment of metastatic breast cancer with vinorelbine and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2006 |
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Survival; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Interleukin-6; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Statistics as Topic; Survival Analysis; Taxoids; Tumor Cells, Cultured | 2006 |
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Hospitals, Community; Humans; Middle Aged; Survival Rate; Taxoids; United Kingdom | 2007 |
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Staging; Southwestern United States; Survival Analysis; Survival Rate; Taxoids; Time Factors | 2006 |
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; ROC Curve; Taxoids; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2006 |
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Taxoids | 2006 |
A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Kidney; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2006 |
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Treatment Failure | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiation-Sensitizing Agents; Retrospective Studies; Severity of Illness Index; Survival Rate; Taiwan; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Floxuridine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids | 2008 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease Progression; Docetaxel; Drug Delivery Systems; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure | 2008 |
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome | 2007 |
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Poland; Taxoids; Vinblastine; Vinorelbine | 2007 |
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Epothilones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2007 |
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2007 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure; Vinblastine; Vinorelbine | 2007 |
Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Pilot Projects; Sample Size; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Taxoids | 2007 |
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2007 |
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Chromogranin A; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2008 |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Irinotecan; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Disease Progression; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis; Taxoids | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2008 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1998 |
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms | 1998 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and b
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Male; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome | 2000 |
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Docetaxel; Female; Fever; Follow-Up Studies; Gastrectomy; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Up-Regulation | 2002 |
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
228 other study(ies) available for docetaxel anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Topics: Androgen Antagonists; Choline; Disease Progression; Docetaxel; Humans; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report.
Topics: Cardiotoxicity; Disease Progression; Docetaxel; Humans; Immune Checkpoint Inhibitors; Myocarditis; Thymoma; Thymus Neoplasms | 2022 |
What's Next for Sotorasib in NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Costs; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Survival Analysis | 2023 |
Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy.
Topics: Androgen Antagonists; Disease Progression; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2023 |
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Topics: Aged; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2019 |
Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Kallikreins; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies | 2019 |
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Computational Biology; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; MicroRNAs; Middle Aged; Prospective Studies; Retrospective Studies | 2019 |
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins | 2020 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom | 2020 |
Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.
Topics: Androgens; Animals; Apoptosis; Cell Movement; Disease Progression; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Mice; Neoplasm Metastasis; Proscillaridin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Machine Learning; Male; Nivolumab; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2020 |
Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Computational Biology; Databases, Genetic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; GABA Plasma Membrane Transport Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Prognosis; Prostatic Neoplasms; Survival Rate; Xenograft Model Antitumor Assays | 2020 |
Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States | 2020 |
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Platinum; Ramucirumab; Taxoids | 2021 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
[Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Pyridines; Stomach Neoplasms | 2020 |
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Topics: Acetylation; Androgen Antagonists; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Survival; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Tubulin | 2020 |
Bile Acid Tethered Docetaxel-Based Nanomicelles Mitigate Tumor Progression through Epigenetic Changes.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; CpG Islands; Demethylation; Disease Progression; Docetaxel; Epigenesis, Genetic; Extracellular Matrix Proteins; Female; Lithocholic Acid; Mice, Inbred BALB C; Micelles; Neoplasms; Surface-Active Agents | 2021 |
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Cell Proliferation; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Models, Theoretical; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Tumor Burden | 2020 |
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors; Tubulin Modulators; Young Adult | 2021 |
Body composition and metastatic prostate cancer survivorship.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Cancer Survivors; Disease Progression; Docetaxel; Humans; Male; Progression-Free Survival; Prostate; Prostatic Neoplasms; Survivorship | 2021 |
[Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Topics: Adenocarcinoma of Lung; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Crizotinib; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Male; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Databases, Factual; Disease Progression; Docetaxel; Europe; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Risk Assessment; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2021 |
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Taxoids | 2017 |
Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
Topics: Androgen Antagonists; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Biological Transport; Cell Line; Disease Progression; Docetaxel; Drug Synergism; Electronic Health Records; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitriles; Organic Anion Transporters; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Time Factors; United States | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Febrile Neutropenia; Gonadotropin-Releasing Hormone; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2018 |
Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2018 |
Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2017 |
Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2018 |
[Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Mice; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2018 |
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Multigene Family; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2019 |
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Docetaxel; Endothelial Cells; Female; Humans; Lymphangiogenesis; Lymphatic Metastasis; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-3 | 2018 |
Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CX3C Chemokine Receptor 1; Disease Progression; Docetaxel; Doxorubicin; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Cells, Circulating; Prognosis; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2018 |
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Cyclobutanes; Disease Progression; Docetaxel; Down-Regulation; Humans; Male; Mice; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prostate; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Transcriptional Regulator ERG | 2018 |
LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Receptors, G-Protein-Coupled; Taxoids; Wnt Signaling Pathway | 2019 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Polyethylene Glycols; Pre-Exposure Prophylaxis; Ramucirumab; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Gene Knockout Techniques; Heterografts; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Seminal Plasma Proteins | 2019 |
A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2019 |
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome | 2019 |
Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Humans; Ifosfamide; Inguinal Canal; Kaplan-Meier Estimate; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Penile Neoplasms; Penis; Taxoids | 2019 |
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Decision-Making; Consensus; Delphi Technique; Disease Progression; Docetaxel; Humans; Immunotherapy; Indoles; Lung Neoplasms; Mutation; Spain | 2020 |
Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Kallikreins; Male; Middle Aged; Neoplasm Staging; Prognosis; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Severity of Illness Index | 2019 |
Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quality of Life; Surgery, Computer-Assisted; Thoracoscopy; Treatment Outcome | 2019 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Disease Progression; Disseminated Intravascular Coagulation; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome | 2013 |
Esophageal mucosal metastasis from adenocarcinoma of the distal stomach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cisplatin; Disease Progression; Docetaxel; Endoscopy, Digestive System; Endosonography; Esophageal Neoplasms; Esophagus; Gastrectomy; Humans; Immunohistochemistry; Male; Middle Aged; Mucin 5AC; Mucous Membrane; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for
Topics: Adult; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Approval; European Union; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androstadienes; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Taxane associated subacute cutaneous lupus erythematosus.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Taxoids | 2013 |
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Castration; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2013 |
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Tumor Burden | 2013 |
Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Docetaxel; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Epothilones; Growth Inhibitors; Humans; Lactones; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microtubules; Multiple Sclerosis; Paclitaxel; Taxoids | 2013 |
Taking a break from chemotherapy to fight drug-resistance: The cases of cancer and HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Resistance, Viral; Humans; Mice; Models, Theoretical; Neoplasms; T-Lymphocytes; Taxoids; Tumor Burden | 2013 |
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Radiation therapy with concurrent retrograde superselective intra-arterial chemotherapy for gingival carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Gingival Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Survival Rate; Taxoids | 2014 |
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Taxoids | 2013 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modality Therapy; Databases, Factual; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2014 |
Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Patient Selection; Retreatment; Taxoids; Treatment Outcome | 2014 |
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Transformation, Neoplastic; Combined Modality Therapy; Disease Progression; Docetaxel; Gene Knockdown Techniques; Gene Silencing; Genetic Therapy; Heterografts; Humans; Male; Mice; Mice, SCID; Mice, Transgenic; NADPH Oxidases; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Prostatectomy; Prostatic Neoplasms; Reactive Oxygen Species; Recurrence; Syndecan-1; Taxoids; Tumor Cells, Cultured | 2013 |
Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Calcium; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Neoplasm Grading; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2014 |
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bronchial Neoplasms; Disease Progression; Docetaxel; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Targeted Therapy; Quinazolines; Remission Induction; Retreatment; Taxoids; Treatment Outcome | 2014 |
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2015 |
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prognosis; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Patient Selection; Taxoids; Treatment Outcome | 2014 |
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Europe; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Topics: Animals; Cell Movement; Cellular Senescence; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunity, Innate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Male; Mice; Myeloid Cells; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Chemokine; Receptors, Interleukin-8B; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Male; Mice; Orchiectomy; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Receptor, IGF Type 1; Signal Transduction; Taxoids; Tumor Burden; Tyrphostins; Xenograft Model Antitumor Assays | 2014 |
Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Survival Rate; Taxoids | 2014 |
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antigen; Male; Mice; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Antitumor Effect of Docetaxel in Osteosarcoma by the Inhibition of Wnt Signal Channel.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Matrix Metalloproteinase 9; Osteosarcoma; Taxoids; Time Factors; Wnt Signaling Pathway | 2015 |
The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemokine CCL20; Disease Progression; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Receptors, CCR6; Signal Transduction; T-Lymphocytes, Regulatory; Taxoids | 2015 |
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Grading; Precision Medicine; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Ductal; Disease Progression; Docetaxel; Humans; Incidence; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 KRAS mutation: a case report with unusual clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Codon; Cystoscopy; Disease Progression; Docetaxel; Fatal Outcome; Female; Gastroscopy; Humans; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Stomach Neoplasms; Taxoids; Urinary Bladder Neoplasms | 2015 |
Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromogranin A; Disease Progression; Disease-Free Survival; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stathmin; Taxoids; Treatment Outcome | 2016 |
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer].
Topics: Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Neoplasm Grading; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Advances in advanced prostate cancer - the continuing journey.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Male; Practice Patterns, Physicians'; Prostatic Neoplasms; Taxoids | 2016 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Taxoids; Tegafur | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Topics: Adenoviridae; Adult; Animals; Antigens, Surface; Antineoplastic Agents; Case-Control Studies; Cell Line, Tumor; Disease Progression; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Genes, Reporter; Glutamate Carboxypeptidase II; Green Fluorescent Proteins; Humans; Kallikreins; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Staging; Neoplastic Cells, Circulating; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Regulatory Elements, Transcriptional; Reproducibility of Results; Taxoids; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Virus Replication; Young Adult | 2016 |
Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Disease Progression; Docetaxel; Gastrin-Releasing Peptide; Humans; Lymphatic Metastasis; Male; Middle Aged; Phosphopyruvate Hydratase; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Male; Middle Aged; Paget Disease, Extramammary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Neoplastic Stem Cells; Prostatic Neoplasms; STAT3 Transcription Factor; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Eye; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nose Neoplasms; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2016 |
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Safety-Based Drug Withdrawals; Taxoids; Time Factors; Treatment Outcome | 2017 |
Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Hungary; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids | 2017 |
Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Computational Biology; Databases, Genetic; Disease Progression; Disease-Free Survival; Docetaxel; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mucin-1; Neoplastic Stem Cells; Neuroendocrine Tumors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Immunohistochemistry; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; SOX9 Transcription Factor; Taxoids; Time Factors; Tissue Array Analysis; Transcriptional Regulator ERG; Treatment Outcome | 2016 |
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
Topics: Aged; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Genotype; Humans; Lung Neoplasms; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Prognosis; Taxoids; Tubulin | 2017 |
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Docetaxel; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Standard of Care; Taxoids; Zoledronic Acid | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclooxygenase 2 Inhibitors; Disease Progression; Docetaxel; Heparin, Low-Molecular-Weight; Humans; Male; Metformin; Models, Theoretical; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Taxoids; Treatment Outcome; Warfarin | 2017 |
PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mitosis; Prognosis; Proto-Oncogene Proteins; Survival Analysis; Taxoids; Young Adult | 2017 |
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Disease Progression; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptor, ErbB-3; Solubility; Survival Analysis; Taxoids | 2008 |
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Disease Progression; Docetaxel; Humans; Isoenzymes; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Taxoids; Time Factors | 2008 |
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab | 2008 |
[Chemotherapy for prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Palliative Care; Patient Care Team; Prostatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Body Fluids; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Fibroblasts; Humans; Metalloproteases; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; NIH 3T3 Cells; Oligopeptides; Ovarian Neoplasms; Peritoneum; Receptor, PAR-1; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2008 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate; Taxoids | 2008 |
Predictive modelling in hormone-refractory prostate cancer (HRPC).
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kinetics; Male; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Taxoids | 2009 |
[Comment to P. J. Olbert et al., page 164].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Controlled Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Survival Rate; Taxoids; Treatment Outcome | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2010 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Humans; Male; Prostatic Neoplasms; Taxoids | 2009 |
[Comparison of therapeutic effects of chemotherapy combined with radiotherapy versus chemotherapy alone in initial treatment of advanced gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Remission Induction; Stomach Neoplasms; Taxoids | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Markov Chains; Pemetrexed; Quality of Life; Quality-Adjusted Life Years; Spain; Taxoids; Treatment Outcome | 2010 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Biomarkers, Tumor; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Middle Aged; Monocarboxylic Acid Transporters; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Up-Regulation | 2010 |
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Salvage Therapy; Spain; Taxoids | 2010 |
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Cost-Benefit Analysis; Disease Progression; Docetaxel; Humans; Immunotherapy; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2010 |
Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Fiducial Markers; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Humans; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Prostatic Neoplasms; Prostatitis; Proton Therapy; Radiation-Sensitizing Agents; Radiotherapy, Image-Guided; Rectum; Taxoids; Treatment Outcome; Urinary Incontinence; Urogenital System | 2012 |
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Genes, BRCA1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Repressor Proteins; Retrospective Studies; RNA, Messenger; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; C-Reactive Protein; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2010 |
Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids; Uterine Cervical Neoplasms | 2011 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Docetaxel; Female; Humans; Luciferases; Luminescent Agents; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Pyrazoles; Reproducibility of Results; Taxoids; Transfection | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Watchful Waiting | 2011 |
Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Disease Progression; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Matrix Metalloproteinase 11; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cytochrome P-450 CYP3A; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2011 |
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Humans; Hyaluronan Receptors; Isoenzymes; Neoplastic Stem Cells; Phenotype; Prognosis; Retinal Dehydrogenase; Taxoids | 2011 |
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
[Radiochemotherapy in non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pneumonectomy; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids; Tomography, X-Ray Computed | 2011 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance.
Topics: Animals; Cell Movement; Cells, Cultured; Coloring Agents; Disease Progression; Docetaxel; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Endothelial Cells; Evans Blue; Extracellular Fluid; Fatty Acids, Omega-3; Female; Human Umbilical Vein Endothelial Cells; Humans; Mammary Neoplasms, Animal; Neoplasm Metastasis; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Permeability; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Palliative Care; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cyclophosphamide; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Taxoids; Time Factors; Trastuzumab | 2011 |
Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transdifferentiation; Chromosome Aberrations; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Gene Rearrangement, B-Lymphocyte; Humans; Hypopharyngeal Neoplasms; Immunophenotyping; Karyotyping; Langerhans Cell Sarcoma; Leukemia, Hairy Cell; Mutation; Neoplastic Stem Cells; Pyriform Sinus; Taxoids | 2012 |
Systemic taxotere chemotherapy for metastatic tumor pleurisy in cats with spontaneous breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cats; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Mammary Neoplasms, Experimental; Neoplasm Metastasis; Pleura; Pleurisy; Taxoids; Treatment Outcome | 2011 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leukopenia; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Male; Middle Aged; Multivariate Analysis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2012 |
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Transformation, Neoplastic; Disease Progression; Docetaxel; Drug Synergism; Gossypol; Humans; Male; Mice; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Signal Transduction; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Neoplastic Stem Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Notch; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2012 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Liposomes; Male; Mice; Mice, Nude; Neoplasm Grading; Oligonucleotides, Antisense; Predictive Value of Tests; Prostatic Neoplasms; Protein Array Analysis; Radiotherapy, Adjuvant; Taxoids; Transplantation, Heterologous; Up-Regulation | 2013 |
Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Membrane; Dietary Supplements; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Ferritins; Green Fluorescent Proteins; Humans; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Taxoids | 2013 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Colony-Forming Units Assay; Disease Progression; DNA Fingerprinting; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Luciferases; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Organ Specificity; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Tumor Cells, Cultured | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Monosomy; Taxoids; Time Factors; Trastuzumab | 2005 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
Treatment of advanced malignant eccrine poroma with locoregional chemotherapy.
Topics: Acrospiroma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Fluorouracil; Humans; Leg; Male; Skin Neoplasms; Sweat Gland Neoplasms; Taxoids | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorometry; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Quality Control; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 Enzyme System; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptogenic Organizing Pneumonia; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Respiratory Insufficiency; Taxoids; Tomography, X-Ray Computed | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2006 |
[AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2006 |
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Kidney Failure, Chronic; Lung Neoplasms; Lymphatic Metastasis; Renal Dialysis; Taxoids; Time Factors; Tomography, X-Ray Computed | 2007 |
Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Research Design; Survival Rate; Taxoids | 2007 |
Electrolyte abnormalities and progressive renal failure in a cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Creatinine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Drug Administration Schedule; Fibrosarcoma; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Ifosfamide; Inflammation; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Renal Insufficiency; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD4-CD8 Ratio; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Endpoint Determination; Female; Fluorouracil; Humans; Immunotherapy; Killer Cells, Natural; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2007 |
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Young Adult | 2008 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Taxoids; Western World | 1998 |
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Disease Progression; DNA Primers; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Targeting; Genes, bcl-2; Male; Mice; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids | 1999 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |